Suprazygomatic maxillary nerve block in septorhinoplasty.
Not Applicable
Completed
- Conditions
- Anaesthesia
- Registration Number
- PACTR202008687031377
- Lead Sponsor
- Faculty of Medicine Tanta University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Sixty patients
aged 18-60 years
of both gender
classified by the American Society of Anesthesiologists as ASA I-II
scheduled for elective septorhinoplasty surgery under general anesthesia
Exclusion Criteria
patient's refusal
body mass index >35 kg/m2
pre-existing neurological disease
infection at site of the block
coagulopathy
allergy to local anesthetics
chronic analgesic use
inability to express NRS score.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the incidence of emergence agitation
- Secondary Outcome Measures
Name Time Method postoperative pain and total postoperative analgesic consumption
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the analgesic effects of suprazygomatic maxillary nerve blocks in septorhinoplasty?
How does ultrasound-guided maxillary nerve block compare to traditional local anesthetics in postoperative pain management for nasal surgery?
Are there specific biomarkers that predict better outcomes with suprazygomatic nerve block interventions in facial surgery?
What are the potential adverse events associated with suprazygomatic maxillary nerve blocks and how are they managed?
What combination therapies enhance the efficacy of maxillary nerve blocks in reducing emergence agitation after general anesthesia?